Meeting
2014 ASCO Annual Meeting
Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial.
Authors
Shahbal Bill Kangarloo
Alberta Health Services, Tom Baker Cancer Centre, Calgary, AB, Canada
Shahbal Bill Kangarloo , Ella S.M. Ng , Vivien H.C. Bramwell , Kathleen I. Pritchard , Lois E. Shepherd , Dongsheng Tu , Anthony M. Magliocco , Patricia A. Tang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Cancer Prevention/Epidemiology
Track
Cancer Prevention/Epidemiology
Sub Track
Cancer Genetics
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1524)
DOI
10.1200/jco.2014.32.15_suppl.1524
Abstract #
1524
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A prospective study on the effect of endoxifen concentration and CYP2D6 phenotypes on clinical outcome in early stage breast cancer patients receiving adjuvant tamoxifen.
First Author: Anabel Beatriz Sanchez-Spitman
Poster
2023 ASCO Annual Meeting
Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
First Author: Sylvie Giacchetti
Poster
2023 ASCO Annual Meeting
Influence of ovarian function supression on quality of life in breast cancer survivors during adjuvant endocrine therapy.
First Author: Natalija Dedic Plavetic
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci